Published Date: 26-May-2021
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Patient-controlled Analgesic Pumps Market, published by KBV research, The Global Patient-controlled Analgesic Pumps Market size is expected to reach $614.5 Million by 2027, rising at a market growth of 9.6% CAGR during the forecast period.
In 2020, the electronic pumps segment acquired the highest revenue share of the global patient-controlled analgesic pumps market, hence became the leading segment. A high-performance single-chip microcomputer and control circuit are used by electronically patient-controlled analgesic pumps with an aim to efficiently control the infusion flow rate.
On the basis of application, the oncology segment became the leading segment in 2020 by obtaining the highest revenue share of the global patient-controlled analgesic pumps market. PCA pumps are effective in controlling cancer pain by self-administration of intravenous opioids with the usage of a programmable pump. People who are suffering from moderate to acute cancer pain can use patient-controlled analgesic pumps at their homes.
Asia Pacific is expected to witness substantial CAGR during the forecast period. The growth of the regional market is boosted by the growing cases of chronic diseases combined with the growing awareness regarding the latest technologies, particularly in India and China. Moreover, the growth of the regional market is further supplemented by the rising awareness about pain management, and superior healthcare facilities & infrastructure.
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Smiths Group PLC, Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Baxter International, Inc., Becton, Dickinson and Company, Terumo Corporation, Abbott Laboratories, Avante Health Solutions, ICU Medical, Inc., and Ace Medical Co., Ltd.
By End Use
Unique Offerings from KBV Research